Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price.

Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials is interpreted.

View the latest Novo Nordisk A/S (NOVO.B) stock price, news, historical charts, analyst ratings and financial information from WSJ.